Gleevec - $1.51 billion

Gleevec

Company: Novartis
2011 sales: $1.51 billion
Developer: Novartis
FDA approvals: Chronic myelogenous leukemia, 2011; gastrointestinal stromal tumors, 2002; Philadelphia-chromosome positive acute lymphocytic leukemia, 2006; dermatofibrosarcoma protuberans, 2006; certain myelodysplastic/myeloproliferative diseases, 2006; hypereosinophilic syndrome/chronic eosinophilic leukemia, 2006; aggressive systemic mastocytosis, 2006; adjuvant GIST treatment, 2012

Gleevec is one of the revolutionary drugs that has transformed some blood cancers into chronic illnesses rather than death sentences. According to one study cited in Science Life, 5-year survival rates for patients with chronic myelogenous leukemia was 30% before Gleevec. After Gleevec, 89% of patients hit that target.

The story of Gleevec's development has been told, in detail, many times. We won't go into it here (if you're interested in the details, check out this article from Nature.. What we will tell you is that the scientists involved--including researchers from Memorial Sloan-Kettering Cancer Center, Oregon Health & Science University, as well as Novartis ($NVS)--won the prestigious Lasker Award for their achievement.

Right now, Gleevec, which is sold as Glivec in some countries, is in the middle of a big intellectual property battle in India. The Indian government has refused to grant a patent to Novartis for the drug, and for several years now, Novartis has been fighting that decision. It filed an appeal recently, but that's still pending.

 

Gleevec - $1.51 billion
Read more on

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.